How Does Diabetes Affect Daily Life? A Beyond-A1C Perspective on Unmet Needs

• DOI: 10.2337/cd17-0093
• Publication Date: 2018-01-11T01:40:23Z
• Authors: Divya Gopisetty; Brian Levine; Nancy Liu; Phin Younge; Adam Brown; Kelly L. Close; Richard Wood
• Keywords: Lixisenatide; Insulin degludec; Diabetes treatment

IN BRIEF Given the progressive nature of type 2 diabetes, treatment intensification is usually necessary to maintain glycemic control. However, for a variety reasons, often not intensified in timely manner. The combined use basal insulin and glucagon-like peptide-1 receptor agonist recognized provide complementary approach diabetes. This review evaluates efficacy safety two co-formulation products, degludec/liraglutide glargine/lixisenatide, diabetes inadequately controlled on either component agent alone. We consider benefits limitations these medications based data from randomized clinical trials discuss how they may address barriers intensification.